华领医药(2552.HK)公布业绩,2024年是公司核心产品华堂宁®进入国家医保药品目录后的首个完整销售年度。公司销售收入达2.559亿元,较2023年增加234%;共销售约210.5万盒华堂宁®,较2023年增加约740%。华堂宁®的销售覆盖约2700家医院。2025年,华领医药建立了药品市场销售团队,华堂宁®在年初展现出了良好的增长势头,前两月共售出约59.2万盒华堂宁®,净销售额约7320...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.